Premium
The PETALE study: Late adverse effects and biomarkers in childhood acute lymphoblastic leukemia survivors
Author(s) -
Marcoux Sophie,
Drouin Simon,
Laverdière Caroline,
Alos Nathalie,
Andelfinger Gregor U.,
Bertout Laurence,
Curnier Daniel,
Friedrich Matthias G.,
Kritikou Ekaterini A.,
Lefebvre Geneviève,
Levy Emile,
Lippé Sarah,
Marcil Valérie,
Raboisson MarieJosée,
Rauch Frank,
Robaey Philippe,
Samoilenko Mariia,
Séguin Chantal,
Sultan Serge,
Krajinovic Maja,
Sinnett Daniel
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26361
Subject(s) - medicine , psychosocial , neurocognitive , survivorship curve , quality of life (healthcare) , adverse effect , pediatrics , childhood cancer , cancer , psychiatry , cognition , nursing
Background Childhood cancer survivorship issues represent an established public health challenge. Most late adverse effects (LAEs) have been demonstrated to be time and treatment dependent. The PETALE study is a multidisciplinary research project aiming to comprehensively characterize LAEs and identify associated predictive biomarkers in childhood acute lymphoblastic leukemia (cALL) survivors. Methods cALL survivors treated at Sainte‐Justine University Health Center with Dana‐Farber Cancer Institution‐ALL protocols 87‐01 through 2005‐01 were eligible. During Phase I of the study, the participants underwent comprehensive clinical, biologic, and psychosocial investigation targeting metabolic syndrome, cardiotoxicity, bone morbidity, neurocognitive problems, and quality of life issues. Whole‐exome sequencing was performed for all participants. Subjects identified with an extreme phenotype during Phase I were recalled for additional testing (Phase II). Results Phase I included 246 survivors (recall rate 71.9%). Of those, 85 participants completed Phase II (recall rate 88.5%). Survivors agreeing to participate in Phase I (n = 251) were similar to those who refused (n = 31) in terms of relapse risk profile, radiotherapy exposure, and age at the time of study. Participants, however, tended to be slightly older at diagnosis (6.1 vs. 4.7 years old, P = 0.08), with a higher proportion of female agreeing to participate compared with males (93.2 vs. 86.5%, P = 0.07). Conclusion The PETALE study will contribute to comprehensively characterize clinical, psychosocial, biologic, and genomic features of cALL survivors using an integrated approach. Expected outcomes include LAE early detection biomarkers, long‐term follow‐up guidelines, and recommendations for physicians and health professionals.